Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
| Merck & Co. (NYSE: MRK) | Delayed: 148.36 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.36 | 52 Week High | $65.46 | |||
| Open | $148.36 | 52 Week Low | $47.97 | |||
| Day High | $148.36 | P/E | 100.93 | |||
| Day Low | $148.36 | EPS | $1.47 | |||
| Volume | 24,520 | |||||
